Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA Department of Preclinical and Clinical Pharmacology and Headache Center, University of Florence, Florence, Italy Department of Pharmaceutical Chemistry, University of Ferrara, Ferrara, Italy Department of Chemical, Alimentary, Pharmaceutical and Pharmacological Sciences, University of Eastern Piedmont, Novara, Italy Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Pain. 2012 Sep;153(9):1949-1958. doi: 10.1016/j.pain.2012.06.012. Epub 2012 Jul 17.
Activation of transient receptor potential ankyrin-1 (TRPA1) on meningeal nerve endings has been suggested to contribute to environmental irritant-induced headache, but this channel may also contribute to other forms of headache, such as migraine. The preclinical studies described here examined functional expression of TRPA1 on dural afferents and investigated whether activation of TRPA1 contributes to headache-like behaviors. Whole-cell patch-clamp recordings were performed in vitro with 2 TRPA1 agonists, mustard oil (MO), and the environmental irritant umbellulone (UMB) on dural-projecting trigeminal ganglion neurons. Application of MO and UMB to dural afferents produced TRPA1-like currents in approximately 42% and 38% of cells, respectively. By means of an established in vivo behavioral model of migraine-related allodynia, dural application of MO and UMB produced robust time-related tactile facial and hind paw allodynia that was attenuated by pretreatment with the TRPA1 antagonist HC-030031. Additionally, MO or UMB were applied to the dura, and exploratory activity was monitored for 30min with an automated open-field activity chamber. Dural MO and UMB decreased the number of vertical rearing episodes and the time spent rearing in comparison to vehicle-treated animals. This change in activity was prevented in rats pretreated with HC-030031 as well as sumatriptan, a clinically effective antimigraine agent. These data indicate that TRPA1 is expressed on a substantial fraction of dural afferents, and activation of meningeal TRPA1 produces behaviors consistent with those observed in patients during migraine attacks. Further, they suggest that activation of meningeal TRPA1 via endogenous or exogenous mechanisms can lead to afferent signaling and headache.
瞬时受体电位锚蛋白-1(TRPA1)在脑膜神经末梢的激活被认为有助于环境刺激物引起的头痛,但该通道也可能与其他类型的头痛(如偏头痛)有关。这里描述的临床前研究检查了TRPA1 在硬脑膜传入神经上的功能表达,并研究了TRPA1 的激活是否有助于类似头痛的行为。用 2 种 TRPA1 激动剂芥末油(MO)和环境刺激物 Umbellulone(UMB)在体外对硬脑膜投射三叉神经节神经元进行全细胞膜片钳记录。MO 和 UMB 应用于硬脑膜传入神经,分别在约 42%和 38%的细胞中产生 TRPA1 样电流。通过建立偏头痛相关感觉过敏的体内行为模型,MO 和 UMB 硬脑膜给药产生了与时间相关的触发性面部和后爪感觉过敏,该感觉过敏可被 TRPA1 拮抗剂 HC-030031 预处理所减弱。此外,将 MO 或 UMB 应用于硬脑膜,并在 30 分钟内使用自动旷场活动室监测探索性活动。与给予载体的动物相比,MO 和 UMB 硬脑膜给药减少了垂直竖起的发作次数和竖起的时间。在用 HC-030031 预处理的大鼠以及临床有效的偏头痛药物舒马曲坦预处理的大鼠中,这种活动变化得到了预防。这些数据表明,TRPA1 在硬脑膜传入神经的很大一部分上表达,并且脑膜 TRPA1 的激活产生与偏头痛发作期间患者观察到的行为一致的行为。此外,它们表明通过内源性或外源性机制激活脑膜 TRPA1 可导致传入信号和头痛。